Chiome Bioscience (TSE:4583) Other Current Payables: 円75.6 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4583 Chiome Bioscience Inc TSE:4583
50 GF Score
Price 円97.00
GF Value 円87.77
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Chiome Bioscience Other Current Payables?

Chiome Bioscience TSE:4583 -2.02% 50 Other Current Payables is 円75.6 Mil as of Jun. 2026. GuruFocus rates TSE:4583 with a GF Score™ of 50/100 and a GF Value™ of 円87.77 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Chiome Bioscience's Other Current Payables for the quarter that ended in Jun. 2026 was 円75.6 Mil.

Chiome Bioscience's quarterly Other Current Payables declined from Dec. 2025 (円82.5 Mil) to Mar. 2026 (円62.3 Mil) but then increased from Mar. 2026 (円62.3 Mil) to Jun. 2026 (円75.6 Mil).

Chiome Bioscience's annual Other Current Payables increased from Dec. 2023 (円117.0 Mil) to Dec. 2024 (円138.1 Mil) but then declined from Dec. 2024 (円138.1 Mil) to Dec. 2025 (円82.5 Mil).

Chiome Bioscience Other Current Payables Related Terms

Chiome Bioscience Other Current Payables Historical Data

* Premium members only.

The historical data trend for Chiome Bioscience's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chiome Bioscience Other Current Payables Chart

Chiome Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 81.55 70.80 116.95 138.10 82.52

Chiome Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.87 107.26 82.52 62.33 75.55
TSE:4583
50GF Score
Chiome Bioscience Inc TSE:4583
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chiome Bioscience Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of 円75.6 Mil mean?
Chiome Bioscience (TSE:4583) has a Other Current Payables of 円75.6 Mil as of Jun. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Chiome Bioscience and its competitors.
Is Chiome Bioscience's Other Current Payables too high?
Chiome Bioscience's current Other Current Payables is 円75.6 Mil. Overall, Chiome Bioscience has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Other Current Payables compare to VRTX and REGN?
Chiome Bioscience's Other Current Payables of 円75.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Chiome Bioscience and its competitors. Chiome Bioscience's current Other Current Payables is 円75.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Modestly Overvalued. The stock's GF Value™ is 円87.77, compared to a current price of 円97.00 — trading 10.5% above its estimated fair value. The current Other Current Payables is 円75.6 Mil. Chiome Bioscience's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Other Current Payables is 円75.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chiome Bioscience (TSE:4583) Overvalued in 2026?

Based on GuruFocus' analysis, Chiome Bioscience stock appears to be overvalued. The current stock price of 円97.00 is trading 10.5% above its estimated GF Value™ of 円87.77. GuruFocus considers Chiome Bioscience to be Modestly Overvalued.

Key valuation signals for TSE:4583:

  • Other Current Payables: 円75.6 Mil
  • GF Value™: 円87.77 vs. price of 円97.00 (10.5% above fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chiome Bioscience Business Description

Address 3-12-1 Honmachi, No. 6, Sumitomo Fudosan Nishi Shinjuku Building, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
50GF Score

Get the complete analysis for TSE:4583

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円97.00
Price
円87.77
GF Value